Trial registration: ClinicalTrials.gov NCT05179889, registered on 17 December 2021.Lee, Kyung-HaYang, In JunHa, Gi WonLee, JaeimPark, Youn YoungLee, Suk HwanLee, Jong MinBae, Jung HoonPark, Eun JungKim, HyungjinBMC Cancer
High-risk stage III colon cancer has a considerably poorer prognosis than stage II and low-risk stage III colon cancers. Nevertheless, most guidelines recommend similar adjuvant treatment approaches for all these stages despite the dearth of research focusing on high-risk stage III colon cancer and ...
mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, ... KH Lee,YK Ji,IJ Yang - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 Long-term neurotoxicity effects of oxaliplatin added to...
Conclusions and Relevance Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials. Trial Registration ClinicalTrials.gov Identifier: NCT01591733...
Discussion The Frost trial would help determine the oncologic efficacy and safety of adjuvant triplet chemotherapy for high-risk stage III colon cancers and ultimately improve prognoses. Trial registration ClinicalTrials.gov NCT05179889, registered on 17 December 2021. *Correspondence: Ji Yeon ...